Many attempts have been made to investigate the immune responsiveness in relation to the development and course of cancer in animal tumour models and in man (Hellstrom and Hellstrom, 1974; Herberman, 1974; Price-Evans, 1976) . In these studies an in-vitro test, such as antigeninduced lymphocyte transformation reaction, can be used for T-lymphocyte function. The possible importance of the role of T-lymphocytes in the humoral immune response acting on B-lymphocytes producing antibodies against thymus dependent antigens is less often studied in tumour bearing individuals. Our purpose was to investigate the class-specific humoral immune response of patients with bronchial carcinoma in relation to the specific cellular immune reactivity after immunisation with a primary test antigen.
It is generally agreed that the test antigen used in these studies is important in assessing the results. Among others (VX 174) haemocyanin from Helix pomatia can be used to test the primary, thymus dependent, antibody response (De Gast et al, 1973) . Helix pomatia haemocyanin (HPH) is a macromolecular respiratory protein from the Roman snail (Helix pomatia), which can easily be isolated and has known physical and chemical properties. It can be used as a non-toxic strong primary immunogen. The assessment of classspecific antibody titres to HPH in healthy adults was recently studied in our laboratory, using the enzyme-linked immunosorbent assay (ELISA) (Weits et al, 1978) . This ELISA technique is a sensitive and relatively simple quantitative test (Engvall and Perlmann, 1972; Bulletin World Health Organisation, 1976; Ruitenbeek et al, 1976 HPH was provided by the biochemical department of the University of Groningen and used in purified form as described by De Gast et al (1973) .
Patients were immunised when the diagnosis was established (before any treatment was started) with 1 mg HPH subcutaneously in the deltoid region as described by De Gast et al (1973) .
Serum for antibody titre determination was collected before and two, eight, and 14 weeks after immunisation. Two Quantitative differential leucocyte counts were performed using the spin-smear method to avoid unequal distribution of the different cell types in the spreads on the glass slides. We consider the counted leucocytes as a random sample of those in the smear and make the extent of the inaccuracy that is inevitably inherent in the method used for differential counts as small as possible (Rumke et al, 1975) . Two hundred cells were counted twice in different randomised chosen fields. The mean value of the counted percentages of lymphocytes was used.
ANTIBODY DETERMINATION
The method of antibody determination was described by Weits et al (1978) . The indirect ELISA technique was performed in round-bottom microtitre plates (Greiner, M 24-AR). Coating with antigen was obtained with 01 mg HPH in 0-1 ml 0-1 M NaHCO3 with 002% sodiumazide at pH 9-6 during incubation overnight at 40C. The plates were washed with tap water and 0-1 ml aliquots of doubling serum dilution starting with 1:10 were then added. After washing 0-1 ml of 1: 5000 diluted, monospecific rabbit antihuman IgG, IgM (Central Bloodtransfusion Service, Amsterdam, batch numbers or IgA antiserum (prepared in our own laboratory) was added and incubated for 45 min at 370C. After washing 0-1 ml, 1: 2500 diluted, peroxidase labelled sheep anti-rabbit antiserum (Institut Pasteur, Paris, batch no 09-7502), diluted in PBS 0-01 M+2% BSA, was added. Incubation was performed at 370C for 45 min. After the last washing 0-1 ml of a 5-aminosalicylic acid 0-08% and hydrogen-peroxidase 0-05% solution, 9: 1, pH 6 00 were allowed to react for one hour, after which time either the results were read immediately or the reaction was stopped by adding 10 ul N NaOH. (Kamo et al, 1957) . Mitchell et al (1976) have reported that in tumour-bearing mice both antigen and antibody were necessary to produce inhibition of "armed" cytotoxic cells through mechanisms that appear to affect an intermediary thymusdependent suppressor cell. The same sort of antibody-induced mechanisms were suggested by Gershon et al (1974) .
This study of immune responsiveness to HPH of patients with squamous-cell bronchial carcinoma showed changes in the humoral and cellular response in different stages of the disease. The results were compared with values obtained in a matched control group because it is important to select such a group by factors that can probably influence immunocapacity as well as the development and occurence of lung cancer (Wal et al, 1966; Cohen et al, 1977) .
The changes in the humoral immune response two weeks after immunisation consisted of a decreased class-specific IgG and IgA antibody response in patients with disseminated disease (stage III) in combination with a relatively high IgM anti-HPH antibody response. Although normal IgG and IgA anti-HPH antibody titres were found at the peak response two weeks after immunisation in patients with localised disease (stage I), a more rapid decline in these antibody titres was shown at eight and 14 weeks after immunisation. These differences in titre decline between patients and controls occurred despite apparent total removal of the tumour, and we consider they were not caused by sur-gical intervention as we have shown no such changes in an additional control group of seven patients who underwent thoracotomy for benign pulmonary disease (unpublished data).
Titre decline studies in stage III patients were not feasible because of the adjuvant chemotherapy and radiotherapy given in that group. Primary cellular immune capacity measured by in-vitro lymphocyte stimulation two weeks after HPH immunisation was significantly decreased, but this was more pronounced in stage III patients.
The findings obtained in the present study are partly in agreement with a previous study in melanoma patients (Anderson et al, 1970; Geha et al, 1974; Janossy et al, 1975; Herber-Katz and Wilson, 1976) . HPH has such properties of a thymus-dependent antigen (De Gast et al, 1973; Weits et al, 1978) .
Our studies suggest that defects in T-helper cell function may give rise to decreased thymusdependent antibody formation. Since IgG and IgA antibodies are generally thymus-dependent and IgM antibodies more thymus-independent, our findings in the patients with disseminated disease may reflect a decreased T-helper function in these patients. The decreased HPH-induced lymphocyte stimulation found in our patients may be an additional argument for defective T-cell function, as sensitised T-cells seem to be necessary for antigeninduced lymphocyte stimulation (Geha et al, 1973) .
On the other hand, it has recently been shown that in tumour-bearing animals reactive T-cells did recognise tumour cell immunogens as strong antigens but failed to co-operate with B-cells for an antibody response against the tumour cells (Dennert et al, 1977) , which is necessary to "arm" the FC-receptor on T-cell subpopulations with these antibodies to direct their cytotoxic activities against tumour cells (Saal et al, 1977) . There is evidence that this disturbance in T-cell function is a consequence of the activation of suppressor Tcells by the tumour (Reinisch et al, 1977 (Jansen et al, 1977) . The presence of these circulating complexes was related to the extent of tumour burden. So the diminished thymusdependent antibody production in bronchial carcinoma patients may be an IgG-immune complex-induced hyperactivity of suppressor T-cell function leading to a more rapid decline of specific, thymus-dependent antibody formation and decreased HPH-induced lymphocyte stimulation, already demonstrable in stage I of the disease after removal of the tumour but still more pronounced in stage III.
In conclusion changes in the thymus-dependent primary humoral and cellular immune response were found in patients with squamous-cell bronchial carcinoma related to the extent of the disease. The results suggest that in these patients a decreased T-helper function exists, which is possibly a consequence of an immune complex activated T-suppressor cell. 
